Headquartered in Singapore, Nova Satra Dx is dedicated to empowering patients and physicians by researching, developing, and commercializing advanced diagnostic tests. Their tests utilize Asian-specific epigenetic biomarkers, providing fast and precise cancer detection. Leveraging the clinically validated NovoTect™ technology from the University of Oxford, Nova Satra Dx identifies changes in gene expression associated with various cancers. Their pipeline includes tests for breast, colon, prostate, stomach, and lung cancers. By utilizing stable DNA-based targets and chromosomal signatures, their epigenetic platform technology enables accurate diagnosis and early-stage cancer detection, ultimately improving lives through cancer detection. For more information, visit www.novasatra.com.